{"id":"NCT04132050","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788","officialTitle":"A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-24","primaryCompletion":"2021-12-21","completion":"2023-09-25","firstPosted":"2019-10-18","resultsPosted":"2025-08-11","lastUpdate":"2025-08-11"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"R788","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"R788","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788 compared with placebo, and to investigate the safety and efficacy of long term dosing of R788 in patients with chronic idiopathic thrombocytopenic purpura.","primaryOutcome":{"measure":"Achievement Rate of Stable Platelet Response","timeFrame":"24 weeks (Period I)","effectByArm":[{"arm":"R788 Group","deltaMin":36.4,"sd":null},{"arm":"Placebo Group","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.030"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":22},"commonTop":["Diarrhoea","Hypertension","Constipation","Eczema","COVID-19"]}}